In our study, no findings were observed regarding unsafe use of ECT during pregnancy.
INTRODUCTION
ECT is one of the earliest medical treatments, which is based on electrical stimulation of the brain tissue causing generalized convulsions. It has been utilized in the treatment of psychiatric disorders since 1938 (1) . Although, through the introduction of the psychotropic medications the use of ECT has been less desirable, after the 1980's due to the insufficient therapeutic effects of these medications, ECT applications resurged (2) . Psychotic depression, suicidal tendency, untreatable manic attacks, catatonic schizophrenia, affective disorder, catatonic cases with somatic etiologies, delirium, psychiatric and neurologic disorders such as neuroleptic malign syndrome (NMS) may be cited among the applications of ECT (3) (4) . Due to rapidity of response and excellent safety profile, ECT is the most preferred treatment among the elders with concurrent diseases (5) .
The treatment of psychiatric disorders in pregnancy poses a challenge. Pharmacological treatment of psychiatric disorders in pregnant women is complicated by potential untoward effects of medications on the fetus, including morphologic and behavioral teratogenicity, toxicity, and withdrawal syndromes (5) .
All medications carry potential risk. ECT has been demonstrated to be effective and safe in the treatment of major depressive disorder and other mental disorders such as bipolar affective disorders, psychotic depression, and schizophrenia (6-7); however, reports of its efficacy and possible risks during pregnancy are scarce and there have been no controlled, prospective trials evaluating its use in pregnant women.
In the literature, there are cited cases regarding such applications of ECT. One of these studies that has been published by Miller, includes 300 ECT cases between 1942-1991. Out of the 28 (9.3%) of the 300 cases, complications have been reported, however, in most of these cases no direct relationship with ECT has been determined (8) . pregnant patients who were treated with ECT for their mood disorders. In these cases only one patient's pregnancy was terminated early, and the rest of the patients did not experience any complications even after delivery.
Our purpose in this study was to investigate the safety and complications of ECT on the inpatient pregnancy cases, during the pregnancy, delivery and postpartum phases.
MATERIALS AND METHODS
In this study, we included all of the pregnant patients who were treated with ECT during between 2006 and 2012 at BRSHH. There were no exclusion criteria. This is a retrospective study and BRSHH ethics committee has approved the study. There were no including and excluding criteria. There was no relation between the ECT indications and our study. The main reason for deciding ECT treatment in all cases was their pregnancy. Under these conditions, we found 25 cases. We reviewed all the medical records of these patients and talked some of them, which could be accessed.
All patients were examined by physicians from obstetric and gynecology clinic to ensure that they were eligible for ECT.
ECT Procedure
Prior to the application of ECT, physical and laboratory evaluations, internal medicine and other consultations as required were completed. One day prior to the first scheduled ECT application anesthesiology consultation was performed.
Patients with no contra-indications are refrained from food 6 hours prior to the procedure and their bladders were depleted. The procedure is attended by an anesthetist, a psychiatrist, and a nurse.
Prior to the ECT procedure, the standard anesthetic monitoring and venous line opening were done. As the anesthetic induction is initiated, for a period of 2-3 minutes 
Statistical Analysis
We used SPSS PC 15.0 Windows version for the statistical descriptive analysis, which involved frequency, arithmetic mean, and standard deviation. There were 4 patients with no pharmacotherapy applied during and after ECT.
RESULTS
Two of these patients have no complications, but we have no information about the other two cases.
In one case, who was using sertraline 50 mg/day, and alprazolam 0.5 mg/day during ECT, the newborn was healthy and the delivery was normal.
In the other two cases, because of the haloperidol that was started after the admission to the hospital, EPS symptoms were observed and the haloperidol was replaced with 300-900 mg/day of quetiapine. In one of these, the pregnancy was still continuing, and in the other case there was stillbirth 15 weeks after of the last ECT session.
17 patients were treated with haloperidol and biperiden.
One of these, two days after the 8 th ECT session, was transferred to OB/GYN (obstetric and gynecology clinic) with the suspicion of early membrane rupture. In all of the cases, there were no gynecological-obstetric pathologies, the pseudocholinesterase levels were normal (min 4116 IU/lt, max 7790 IU/lt), propofol and succinylcholine were used as the anesthetic agents. The average number of ECT session was 7.32 (between [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In all of the cases, the average Except for the case with the early membrane rupture suspicion, in all of the cases no pregnancy related complications have been observed until the discharge.
Regarding the delivery and post delivery period, 17 cases were followed. In 13 of these, the newborns were alive and healthy; in one case there was stillbirth 16 weeks after the ECT application. In one of these cases that were admitted twice for ECT, the newborn was observed to have intrauterine developmental insufficiency (below 3 percentile at birth).
However, in the first year follow up, the baby has reached proper percentile levels. In one of the cases the pregnancy was still continuing.
DISCUSSIONS
In this study, we have investigated the safety of ECT applications on in-patient pregnancy cases at BRSHH. We have investigated the progress of the pregnancy and the probable effects on the fetal health status.
Only one out of the 25 cases, following the 8 th ECT session at the 32 nd week of pregnancy, was discharged with the suspicion of early membrane rupture (EMR). In the literature, it is mentioned that the oxytocin levels peak post ECT application, causing intrauterine contractions and premature birth (11, 12) . In our case, EMR had occurred after the 8th ECT session, so it could be in relation with ECT. In the literature, premature contractions and preterm labor ratio was 3.5% (9) . In all of the births, early membrane rupture and preterm labor have been seen 2-3% (13). In our study, this ratio is 1/16 (6.25%). Our ratio is higher than the literature;
the small number of sample in our study can explain this situation. The small number of sample is a limitation of our study. So we could not be excluded the association between premature rupture of membranes and preterm labor with ECT. In the literature there is no information about the relationship between schizophrenia and EMR in pregnant women. More research is needed on this issue. The case with EMR is the only case with post ECT complication.
17 cases who were followed before and after their delivery; in one case, 16 weeks after the final ECT application, still-birth has occurred. Considering no other developmental defects their regular OB / GYN exams during the 16-weeks period, it is thought that this situation was unrelated to the ECT application. In another case, the weight of the newborn was under 3-percentile rank which was attributed to the insufficient intrauterine growth. Parental percentile ranks were also low. This leads to considering familial rather than ECT related causes. In addition, postnatal exams indicate normal developmental milestones. In our study, we have not observed any complications due to other concurrent diseases in conjunction with ECT.
The same anesthetic agent, propofol, has been used in all of the cases. Propofol is a short acting general anesthetic, easily permeable through the placenta (14) . Nevertheless, fetal and newborn blood levels were lower than the maternal propofol levels (15) . Rapid application of propofol just before the delivery, causes fetal bradycardia (16) . For this reason, fetal heart rate monitoring is necessary during the administration of propofol (17) . However, as the propofol doses applied during ECT is only half of the doses used during the cesarean operations, the risk of fetal bradycardia is considered to be very low and, consequently, no fetal heart rate monitoring was needed. We did not monitor the fetal heart rate and this is another limitation of our study.
Succinylcholine, which is applied to limit the motor activity during ECT, permeates the placental barrier considerably low and has no teratogenic effects (18, 19) . As the same anesthetic agent and muscle relaxant, dosed based on the body weight, have been administered in all of the cases, no correlation with the complications and these agents is considered.
One of the limitations of our study is the absence of the measurement of the fetal heart rate and uterine contraction monitoring. Another limitation is the lack of the maternal follow up in some of the cases. In addition, postnatal neurodevelopmental exams have not been performed in some of the cases. The risks of the usage of the drug therapies during pregnancy have been well-studied as compared to the ECT. For this reason, the consensus is for the use of the drug therapy unless indicated otherwise based on the riskbenefit analysis on a case-by-case basis (20) .
CONCLUSION
Only 2 of the cases that we included the study had complications. One of the complications was stillbirth. But we thought that, it was not related with ECT. Because the time (16 weeks) between the last ECT session and the stillbirth. Other complication was EMR. It had proceeded from the 8th ECT session. In the literature, it is mentioned
